3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
CNS
1
Conditions
Recurrence
1
Marijuana Abuse
1
Glioblastoma
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
73
Temozolomide
68
Specimen Handling
48
Radiotherapy
40
Radiosurgery
29
Bevacizumab
26
Radiation
25
Cyclophosphamide
25
Nivolumab
21
Biopsy
21
pembrolizumab
20
Carboplatin
16
X-Rays
14
Lomustine
13
Ipilimumab
13
fludarabine
12
Irinotecan
12
Vincristine
11
Topotecan
11
Surgical Procedures, Operative
11
Cisplatin
11
Blood Specimen Collection
11
trametinib
9
dinutuximab
9
Immunoglobulin G
8
Etoposide
8
Doxorubicin
8
lutetium Lu 177 dotatate
7
fludarabine phosphate
7
atezolizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
nabiximols
×
CNS
×
90 days
×
Clear all
NCT05629702
2026-05-05
ARISTOCRAT
University of Birmingham
Phase 2
Recruiting
120 enrolled